Apart from solid tumors,MED12 mutations recently were also detected in a significant percentage of roughly 5–9% of chronic lymphocytic leukemias (CLL) (Guièzeet al., 2015;Kämpjärviet al., 2015;Wuet al., 2017a). The gene discussed is MED12; the disease is B-cell chronic lymphocytic leukemia.